294 related articles for article (PubMed ID: 25375891)
21. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies.
De Raeve H; Van Marck E; Van Camp B; Vanderkerken K
Histol Histopathol; 2004 Jul; 19(3):935-50. PubMed ID: 15168356
[TBL] [Abstract][Full Text] [Related]
22. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
Simone V; Brunetti O; Lupo L; Testini M; Maiorano E; Simone M; Longo V; Rolfo C; Peeters M; Scarpa A; Azzariti A; Russo A; Ribatti D; Silvestris N
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212293
[TBL] [Abstract][Full Text] [Related]
23. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
24. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules.
Zachary I
IDrugs; 2003 Mar; 6(3):224-31. PubMed ID: 12789611
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?
Raben D; Helfrich B
Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417
[TBL] [Abstract][Full Text] [Related]
27. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
28. Angiogenesis in multiple myeloma.
Rajkumar SV; Kyle RA
Semin Oncol; 2001 Dec; 28(6):560-4. PubMed ID: 11740809
[TBL] [Abstract][Full Text] [Related]
29. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
30. Antiangiogenesis, anti-VEGF(R) and outlook.
Petersen I
Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926
[TBL] [Abstract][Full Text] [Related]
31. The role of angiogenesis in solid tumours: an overview.
Makrilia N; Lappa T; Xyla V; Nikolaidis I; Syrigos K
Eur J Intern Med; 2009 Nov; 20(7):663-71. PubMed ID: 19818284
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibitors and modulators of angiogenesis in multiple myeloma.
Ferrarini M; Ferrero E
Curr Med Chem; 2011; 18(34):5185-95. PubMed ID: 22087819
[TBL] [Abstract][Full Text] [Related]
33. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Schweizer MT; Carducci MA
Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
[TBL] [Abstract][Full Text] [Related]
34. Targeting VEGF in lung cancer.
Das M; Wakelee H
Expert Opin Ther Targets; 2012 Apr; 16(4):395-406. PubMed ID: 22439677
[TBL] [Abstract][Full Text] [Related]
35. Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma.
Tsirakis G; Pappa CA; Kanellou P; Stratinaki MA; Xekalou A; Psarakis FE; Sakellaris G; Alegakis A; Stathopoulos EN; Alexandrakis MG
Hematol Oncol; 2012 Sep; 30(3):131-6. PubMed ID: 21919032
[TBL] [Abstract][Full Text] [Related]
36. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
39. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
Cao Y; Liu Q
Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
